PHILADELPHIA — Josep Dalmau, MD, PhD, an adjunct professor of neurology and founder and director of the Penn Center of Autoimmune Neurology in the Perelman School of Medicine at the University of Pennsylvania, will be honored as a recipient of the American Academy of Neurology’s 2016 Cotzias Lecture and Award, at the organization’s 68th annual meeting taking place April 15-21 in Vancouver.
Josep Dalmau, MD, PhD
The Cotzias Lecture and Award is named for George C. Cotzias, MD, (1918-1977), who together with colleagues, developed L-Dopa treatment, the most commonly used intervention for Parkinson's disease.
Dalmau will deliver the lecture “Antibody mediated disorders of the synapse” at the Presidential Plenary Session on Sunday, April 17, 9:00 a.m.-12:00 p.m.
In the last nine years Dalmau has identified nine autoimmune brain diseases. He is a world authority on autoimmune and paraneoplastic disorders affecting the nervous system, a group of rare immune responses that attack the brain and spinal cord, including in people who have cancer and benign tumors. These disorders often cause encephalitis (inflammation of the brain) and can hamper memory, thinking skills, sensory perception, muscle movement, coordination, and bowel and bladder functions. They can result in difficulty speaking and breathing and cause personality changes, mood disturbances, seizures, hallucinations, spasms, and sleep problems. In some patients cancers associate with these diseases including lung, breast, ovarian, and cancers of the blood.
The Cotzias Lecture will include a discussion of advances in these diseases particularly anti-NMDA receptor encephalitis, an autoimmune neurologic disease first identified by Dalmau and colleagues at Penn in 2007. When the disease is present, the body creates antibodies against NMDA receptors in the brain. Among other things, NMDA receptors control memory and behavior. These antibodies disrupt normal brain signaling and cause psychosis, severe memory problems and other neurologic symptoms. Anti-NMDA receptor encephalitis can affect both men and women; however it is more common among women, including those with an ovarian teratoma, and children, who usually do not have a tumor. The disease was often difficult to diagnose, but a test developed at Penn is now available worldwide. With appropriate treatment, including immunotherapy, more than 81 percent of patients significantly improve and, with a recovery process that takes an average of two years, can fully recover.
In 2015 Dalmau was elected to the National Academy of Medicine (formerly the Institute of Medicine), one of the highest honors in the fields of health and medicine. He has published over 320 manuscripts in leading journals, and his papers are among the most cited his field. In 2015 Dr. Dalmau was listed by Thomson Reuters as one of the most highly cited investigators in the world in the fields of behavior and neuroscience. He has received numerous awards, including the Career Award (European Society of Neuroimmunology), Developmental Clinical Oncology Career Award (American Cancer Society), Frontiers in Clinical Neuroscience Award (American Academy of Neurology), George W. Jacoby Award (American Neurological Association), Editors of Brain Award (Association of British Neurologists), Neuroscience of Brain Disorders Award (McKnight Foundation), and Neuroscience Research Program Award (Charles A. Dana Foundation).
His research has been funded by the National Institutes of Health, the Spanish Health Institute, the Charles A Dana Foundation, the McKnight Foundation, and the American Cancer Society, among others.
Dalmau was born and raised in Barcelona, Spain and received his MD and PhD degrees from the Autonoma University of Barcelona, where he completed a residency in neurology. He trained in neurooncology, a specialty that deals with tumors of the nervous system, at Memorial Sloan-Kettering Cancer Center in New York, where he was later appointed to the faculty. After 11 years at Sloan-Kettering, Dr. Dalmau became co-director of neurooncology at the University of Arkansas for Medical Sciences. In 2002, he moved to the Department of Neurology and Abramson Cancer Center of the University of Pennsylvania. Currently Dalmau combines his activity at the University of Pennsylvania with a position as ICREA Research Professor at IDIBAPS, Hospital Clinic of the University of Barcelona.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.